Great Lakes Advisors LLC Makes New Investment in RxSight, Inc. (NASDAQ:RXST)

Great Lakes Advisors LLC purchased a new stake in RxSight, Inc. (NASDAQ:RXST - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 204,015 shares of the company's stock, valued at approximately $8,226,000. Great Lakes Advisors LLC owned approximately 0.57% of RxSight as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RXST. RiverPark Advisors LLC raised its position in RxSight by 70.0% in the fourth quarter. RiverPark Advisors LLC now owns 668 shares of the company's stock worth $27,000 after acquiring an additional 275 shares in the last quarter. Amalgamated Bank boosted its stake in shares of RxSight by 7.7% during the fourth quarter. Amalgamated Bank now owns 4,148 shares of the company's stock valued at $167,000 after acquiring an additional 298 shares during the last quarter. HighTower Advisors LLC boosted its stake in RxSight by 7.3% in the 3rd quarter. HighTower Advisors LLC now owns 13,256 shares of the company's stock worth $369,000 after buying an additional 899 shares during the last quarter. Swiss National Bank boosted its stake in RxSight by 2.9% in the 4th quarter. Swiss National Bank now owns 45,700 shares of the company's stock worth $1,843,000 after buying an additional 1,300 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in RxSight by 3.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 106,203 shares of the company's stock worth $2,962,000 after buying an additional 3,132 shares during the last quarter. 78.78% of the stock is owned by institutional investors and hedge funds.

RxSight Stock Down 2.6 %

RXST traded down $1.61 during midday trading on Friday, reaching $60.65. 329,785 shares of the company's stock were exchanged, compared to its average volume of 494,398. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of -48.13 and a beta of 1.21. RxSight, Inc. has a one year low of $20.66 and a one year high of $66.54. The business has a 50-day simple moving average of $53.95 and a two-hundred day simple moving average of $45.60.

RxSight (NASDAQ:RXST - Get Free Report) last posted its quarterly earnings data on Monday, May 6th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.08). The firm had revenue of $29.51 million for the quarter, compared to analyst estimates of $27.56 million. RxSight had a negative return on equity of 27.68% and a negative net margin of 44.01%. The business's quarterly revenue was up 68.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.42) EPS. As a group, research analysts anticipate that RxSight, Inc. will post -0.78 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Stifel Nicolaus lifted their price objective on RxSight from $64.00 to $68.00 and gave the company a "buy" rating in a research note on Monday, May 6th. BTIG Research lifted their target price on RxSight from $61.00 to $72.00 and gave the stock a "buy" rating in a research report on Tuesday, May 7th. Oppenheimer boosted their price objective on RxSight from $61.00 to $72.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 7th. Needham & Company LLC upped their price target on shares of RxSight from $64.00 to $75.00 and gave the stock a "buy" rating in a research note on Tuesday, May 7th. Finally, Wells Fargo & Company increased their target price on shares of RxSight from $61.00 to $68.00 and gave the company an "overweight" rating in a research note on Tuesday, May 7th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $60.63.

Insider Transactions at RxSight

In related news, CFO Shelley B. Thunen sold 10,000 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $56.37, for a total value of $563,700.00. Following the sale, the chief financial officer now directly owns 13,691 shares of the company's stock, valued at approximately $771,761.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Shelley B. Thunen sold 10,000 shares of the company's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $56.37, for a total transaction of $563,700.00. Following the sale, the chief financial officer now owns 13,691 shares in the company, valued at approximately $771,761.67. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Ronald M. Md Kurtz sold 40,000 shares of the company's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $60.15, for a total transaction of $2,406,000.00. Following the sale, the chief executive officer now directly owns 764,610 shares in the company, valued at $45,991,291.50. The disclosure for this sale can be found here. Insiders have sold a total of 80,000 shares of company stock valued at $4,494,600 over the last three months. 21.13% of the stock is currently owned by corporate insiders.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.